Cynata Therapeutics (CYP) H2 2026 earnings summary

Executive summary

• The year was marked by disappointing clinical trial results, with both the Phase 2 aGvHD and Phase 3 osteoarthritis trials failing to meet efficacy endpoints, though no new safety concerns were identified.

• In response, a comprehensive restructuring was implemented: all employee positions were made redundant, including the CEO, and the Board reduced in size and waived fees to cut costs.

• The company secured a $600,000 R&D Tax Incentive loan facility, extending its cash runway beyond FY2027, and is now managed directly by the Board.

• The Cymerus™ platform remains the core asset, with ongoing evaluation of strategic options, including potential asset acquisitions or partnerships.

Financial highlights

• Consolidated net loss for FY2026 was $9.25 million, slightly improved from $9.39 million in FY2025.

• Total revenue and other income were $1.79 million, primarily from R&D rebates, down from $2.11 million in the prior year.

• Cash and cash equivalents at year-end were $897,418, down from $5.05 million in FY2025.

• Net assets turned negative, with a net liability position of $553,774 at 30 June 2026 (FY2025: net assets of $5.98 million).

• An impairment expense of $1.35 million was recognized on intangible assets (patents), reflecting reduced economic prospects after failed trials.

Outlook and guidance

• The Board is evaluating options to realize value from the Cymerus™ technology and to acquire or in-license new assets.

• The streamlined cost base and R&D loan facility provide a cash runway extending beyond FY2027.

• Updates on strategic direction and potential transactions will be provided as developments occur.